COST-EFFECTIVENESS OF SUNITINIB AS SECOND-LINE TREATMENT FOR GASTROINTESTINAL STROMAL TUMOR(GIST) IN CHINA

被引：1
|
作者：
Ren, H. [1 ]
Zhang, J. [2 ]
Dong, P. [3 ]
机构：
[1] Pfizer China, Shanghai, Peoples R China
[2] Southern Med Univ, Guangzhou, Guangdong, Peoples R China
[3] Pfizer Investment Co Ltd, Beijing, Peoples R China
来源：
VALUE IN HEALTH | 2015年 / 18卷 / 07期
关键词：
D O I：
10.1016/j.jval.2015.09.1162
中图分类号：
F [经济];
学科分类号：
02 ;
摘要：
PCN145
引用
收藏
页码：A455 / A455
页数：1
相关论文
共 50 条
  • [1] Predictive factors for toxicity and survival of second-line sunitinib in advanced gastrointestinal stromal tumours (GIST)
    Den Hollander, D.
    Van der Graaf, W. T. A.
    Desar, I. M. E.
    Le Cesne, A.
    ACTA ONCOLOGICA, 2019, 58 (11) : 1648 - 1654
  • [2] A cost - Effectiveness analysis model for the second line treatment of gastrointestinal stromal tumours (GIST) in Mexico
    Contreras-Hernandez, I
    Mould-Quevedo, J.
    Salinas-Escudero, G.
    Silva, A.
    Tapia-Valencia, J.
    Davila-Loaiza, G.
    GarduOo-Espinosa, J.
    VALUE IN HEALTH, 2007, 10 (03) : A11 - A11
  • [3] Regorafenib as second-line therapy for imatinib-resistant gastrointestinal stromal tumor (GIST)
    Takahashi, Tsuyoshi
    Nishida, Toshirou
    Kudo, Toshihiro
    Boku, Narikazu
    Honma, Yoshitaka
    Komatsu, Yoshito
    Nakatsumi, Hiroshi
    Matsumoto, Koji
    Onoe, Takuma
    Oki, Eiji
    Nakamoto, Masako
    Fukutani, Miki
    Nomura, Shogo
    Sato, Akihiro
    Naito, Yoichi
    Doi, Toshihiko
    JOURNAL OF CLINICAL ONCOLOGY, 2020, 38 (04)
  • [4] Treatment of advanced gastrointestinal stromal tumors (GIST): Are results of second-line sunitinib therapy related to duration of response of first-line imatinib?
    Katz, Daniela
    Greenberg-Dotan, Sari
    Feldhamer, Ilan
    Bitterman, Haim
    Hammerman, Ariel
    JOURNAL OF CLINICAL ONCOLOGY, 2015, 33 (15)
  • [5] COST-EFFECTIVENESS OF SECOND-LINE VASOPRESSORS FOR THE TREATMENT OF SEPTIC SHOCK
    Lam, Simon
    Barreto, Erin
    Scott, Rachael
    Kashani, Kianoush
    Khanna, Ashish
    Bauer, Seth
    CRITICAL CARE MEDICINE, 2020, 48
  • [6] Cost-effectiveness of second-line vasopressors for the treatment of septic shock
    Lam, Simon W.
    Barreto, Erin F.
    Scott, Rachael
    Kashani, Kianoush B.
    Khanna, Ashish K.
    Bauer, Seth R.
    JOURNAL OF CRITICAL CARE, 2020, 55 : 48 - 55
  • [7] COST-EFFECTIVENESS ANALYSIS OF REGORAFENIB AS A SECOND-LINE THERAPY IN THE TREATMENT OF HEPATOCELLULAR CARCINOMA IN CHINA
    Xiao, D.
    Zhu, S.
    Sun, W.
    Xuan, J.
    VALUE IN HEALTH, 2019, 22 : S187 - S188
  • [8] COST-EFFECTIVENESS OF IMATINIB IN THE TREATMENT OF ADVANCED GASTROINTESTINAL STROMAL TUMORS (GIST): CANADIAN PERSPECTIVE
    El Ouagari, K.
    Huse, D. M.
    ANNALS OF ONCOLOGY, 2008, 19 : 227 - 227
  • [9] Cost-effectiveness (CE) of imatinib (IM) in the treatment of advanced gastrointestinal stromal tumors (GIST)
    Huse, Daniel
    Lenhart, Greg
    Feng, Weiwei
    Blanke, Charles
    Joensuu, Heikki
    Mehren, Margaret V.
    Demetri, George D.
    ANNALS OF ONCOLOGY, 2006, 17 : 162 - 162
  • [10] Surgical debulking of gastrointestinal stromal tumors: Is it a reasonable option after second-line treatment with sunitinib?
    Pantaleo, M. A.
    Di Battista, M.
    Catena, F.
    Astorino, M.
    Saponara, M.
    Di Scioscio, V.
    Santini, D.
    Piazzi, G.
    Castellucci, P.
    Brandi, G.
    Biasco, G.
    JOURNAL OF CANCER RESEARCH AND CLINICAL ONCOLOGY, 2008, 134 (05) : 625 - 630
12345